Selected article for: "clinical management and supportive care"
Author: Yonghao Xu; Zhiheng Xu; Xuesong Liu; Lihua Cai; Haichong Zheng; Yongbo Huang; Lixin Zhou; Linxi Huang; Yun Lin; Liehua Deng; Jianwei Li; Sibei Chen; Dongdong Liu; Zhimin Lin; Liang Zhou; Weiqun He; Xiaoqing Liu; Yimin Li
Title: Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study
  • Document date: 2020_3_6
    • ID: 9ecuca17_34
    Snippet: Although antiviral drugs, including osehamivir and ribavirin had been applied to our patients, to date no effective antiviral to treat COVID-19 has been identified. The current approach to clinical management is general supportive care supplemented with critical care and organ support when necessary. It has been suggested that the administration of high-titer anti-influenza immune plasma derived from convalescent or immunized individuals may be c.....
    Document: Although antiviral drugs, including osehamivir and ribavirin had been applied to our patients, to date no effective antiviral to treat COVID-19 has been identified. The current approach to clinical management is general supportive care supplemented with critical care and organ support when necessary. It has been suggested that the administration of high-titer anti-influenza immune plasma derived from convalescent or immunized individuals may be clinically beneficial for the treatment of SARS, MERS and seasonal influenza (21) (22) (23) . Convalescent plasma was a potential treatment in coronavirus infection and suggested using in COVID-19 (24). Therefore, convalescent plasma of COVID-19 was applied in 6 patients (13.3%) and no transfusion reactions occurred in our cohort. However, according to our data, at this point, our findings could not All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • antiviral drug and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral drug and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and critical care: 1, 2
    • antiviral drug and current approach: 1
    • antiviral drug and high titer: 1
    • antiviral drug and immune plasma: 1, 2, 3
    • clinical management and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical management and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical management and critical care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical management and current approach: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical management and immune plasma: 1, 2
    • clinical management and organ support: 1, 2, 3, 4, 5
    • clinical management and organ support critical care: 1
    • clinical management current approach and critical care: 1
    • clinical management current approach and current approach: 1, 2
    • clinical management current approach and organ support: 1
    • clinical management current approach and organ support critical care: 1
    • convalescent plasma and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • convalescent plasma and current approach: 1, 2, 3